Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sleep Initiation and Maintenance Disorders 1 Neoplasms 1 Lymphoma, Non-Hodgkin 1 Head and Neck Neoplasms 1 Fatigue 1 Depression 1 Breast Neoplasms 1

Interventions

Rituximab 205 Cyclophosphamide 178 Peripheral Blood Stem Cell Transplantation 93 Etoposide 91 fludarabine phosphate 86 Filgrastim 81 Melphalan 62 Vincristine 60 Mycophenolic Acid 58 Busulfan 58 Whole-Body Irradiation 57 Cytarabine 51 Radiotherapy 49 Doxorubicin 49 Cyclosporine 49 Tacrolimus 48 Granulocyte Colony-Stimulating Factor 48 Prednisone 46 fludarabine 45 Bendamustine Hydrochloride 45 Methotrexate 44 Carmustine 36 Antilymphocyte Serum 34 Dexamethasone 32 Bortezomib 29 Gemcitabine 27 ibritumomab tiuxetan 25 Methylprednisolone 23 sargramostim 22 Stem Cell Transplantation 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Lymphoma, Non-Hodgkin × Analgesics × Clear all

NCT00719472 2017-05-15

RATE

Genentech, Inc.

Phase 3 Completed

451 enrolled 11 charts

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡